Literature DB >> 29929531

Investigating the functionality of a ribosome-binding mutant of NAA15 using Saccharomyces cerevisiae.

Sylvia Varland1,2,3, Thomas Arnesen4,5,6.   

Abstract

OBJECTIVE: N-terminal acetylation is a common protein modification that occurs preferentially co-translationally as the substrate N-terminus is emerging from the ribosome. The major N-terminal acetyltransferase complex A (NatA) is estimated to N-terminally acetylate more than 40% of the human proteome. To form a functional NatA complex the catalytic subunit NAA10 must bind the auxiliary subunit NAA15, which properly folds NAA10 for correct substrate acetylation as well as anchors the entire complex to the ribosome. Mutations in these two genes are associated with various neurodevelopmental disorders in humans. The aim of this study was to investigate the in vivo functionality of a Schizosaccharomyces pombe NAA15 mutant that is known to prevent NatA from associating with ribosomes, but retains NatA-specific activity in vitro.
RESULTS: Here, we show that Schizosaccharomyces pombe NatA can functionally replace Saccharomyces cerevisiae NatA. We further demonstrate that the NatA ribosome-binding mutant Naa15 ΔN K6E is unable to rescue the temperature-sensitive growth phenotype of budding yeast lacking NatA. This finding indicates the in vivo importance of the co-translational nature of NatA-mediated N-terminal acetylation.

Entities:  

Keywords:  N-terminal acetylation; N-terminal acetyltransferase; NAA10; NAA15; NatA; Ribosome association; Saccharomyces cerevisiae

Mesh:

Substances:

Year:  2018        PMID: 29929531      PMCID: PMC6013942          DOI: 10.1186/s13104-018-3513-4

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

N-terminal acetylation is one of the most common protein modifications in eukaryotes, occurring on approximately 80–90% of all human proteins [1-3]. The functional consequences of attaching an acetyl group to the N-terminus of proteins are diverse. N-terminal acetylation plays a role in regulating protein properties such as folding [4-9], stability [10, 11], subcellular localization [12-14], complex formation [15, 16], complex stoichiometry [11] as well as regulating gene <span class="Species">expression [17, 18], and actin cytoskeleton dynamics [19]. Moreover, N-terminal acetylation is crucial for normal development of multicellular organisms [20-23]. N-terminal acetylation is carried out by a family of enzymes called N-terminal acetyltransferases (NATs). The biological importance of this protein modification is underscored by the fact that dysfunctional NATs are implicated in a variety of developmental disorders and cancers [24-33]. In most cases the NATs anchor to the ribosome where they act on nascent polypeptides as they emerge from the exit tunnel during translation [1]. The enzyme complex NatA is one of the main contributors of N-terminal acetylation [34, 35]. It acetylates N-termini after the initiator methionine has been cleaved of by <Species">span class="Chemical">methionine aminopeptidase, thus exposing a small N-terminal amino acid (Ser, Ala, Gly, Thr, Val or Cys) [35-37]. The NatA complex is composed of the catalytic subunit Naa10 (Ard1 in yeast) and the auxiliary subunit Naa15 (Nat1) [36, 38–40], both of which are evolutionarily conserved [35]. Structure analysis of the NatA complex from the fission yeast Schizosaccharomyces pombe (Sp) revealed that Naa15 contains 13 conserved tetratricopeptide repeats (TPR) that wraps around Naa10 in a ring-like manner [41]. The binding of Naa15 induces an allosteric change in the active site of Naa10, which is essential for catalysis by the NatA complex. Thus, Naa15 is considered a regulatory switch that controls NatA activity. Moreover, Naa15 mediates ribosomal anchoring and interacts with nascent polypeptide [40]. It is thought that Naa15 binds to the general docking site for ribosome-associated factors Rpl25/35 (L23/L29), which is favorable positioned in close proximity to the ribosomal exit tunnel [42, 43]. To gain a better understanding for the molecular basis that underlies the interaction between NATs and the ribosome, Magin and colleagues carried out a conservation and electrostatic surface analysis of NatA [44]. Focusing on <Species">span class="Gene">Naa15, they identified two conserved electropositive regions (EPR) on the surface of NatA that appeared responsible for ribosome interaction. Both regions are situated on the same side of the enzyme and would optimally position the active site of ribosomal-bound Naa10 to emerging nascent polypeptides. EPR1 is located within the N-terminal domain of Naa15 and includes the first three TPRs while EPR2 consist of an internal basic α-helix that is situated near the C-terminus. By performing mutation analyses of EPR1 and EPR2 the authors generated a SpNaa15 mutant that retained its ability to bind Naa10 and further full enzymatic activity in vitro, but was unable to associate with ribosomes [44]. The functional impact of this ribosome-binding mutant of SpNaa15 in vivo is yet to be investigated. In this study, we have investigated the functionality of a SpNaa15 mutant that is unable to bind ribosomes. We show, using the budding <Species">span class="Species">yeast Saccharomyces cerevisiae (Sc) as a model, that EPR1 and EPR2 contain important functional regions required for NatA activity in vivo. This study highlights the importance of NatA-mediated N-terminal acetylation taking place during protein synthesis.

Main text

Methods

Yeast strains, plasmid construction, and transformation

The Species">Saccharomyces cerevisiae strain W303-1A (MATa; ade2-1; ura3-1; his3-11,15; leu2-3,112; trp1-1; can1-100) was used to construct a ScNatAΔ strain (<Species">span class="Gene">ard1-Δ::LEU2; nat1-Δ::kanMX) [35]. Gene deletions were verified by colony PCR using primers ARD1-176 F (5′-GTCTTTATTGATCTCTAGGCTCAATCC-3′) with ARD1 848 R (5′-CCTTACTATTCATGCTCACACAATTC-3′) and NAT1 -213 F (5′-CCAAATTGCATGACCTTGCTAATGAGG-3′) with NAT1 2763 R (5′-GGAAAGCAAGAATTTTGGCAAGAAAAGG-3′). The S. cerevisiae expression vector pBEVY-U-SpNatA was generated by inserting a C-terminally truncated version of SpNAA10-V5 (residues 1–156 out of 177 total residues) after the ADH1 promoter using the XmaI/EcoRI sites and full-length HA-SpNAA15 (residues 1–729) after the GPD promoter using the XbaI/SalI sites. pBEVY-U-SpNatA was used to construct pBEVY-U-SpNatA-ΔN-K6E (p.SpNaa15 aa1_109del, K605E, K606E, K609E, K610E, K612E, K613E) in a three-step process using the Q5 site-directed mutagenesis kit (NEB, #E0554S) with the following mutagenic primers: (i) SpNAA15 aa1_109 del F (5′-AACAACTCGAGTCTTTTGCG-3′) with SpNAA15 aa1_109 del R (5′-AAGGGCCTGTACAGCGTAAT-3′), (ii) SpNAA15 aa605_613del F (5′-GACCTTAGTAAACGATTGGAACG-3′) with SpNAA15 aa605_613del R (5′-TTCCTCTTCTTCATTTATTTCTCCAC-3′), and (iii) SpNAA15 aa605_613ins F (5′-agaactcgaagaaGACCTTAGTAAACGATTGG-3′) with SpNAA15 aa605_613ins R (5′-tcataaatttcttcTTCCTCTTCTTCATTTATTTCTC-3′). Mutants were confirmed by sequencing. pBEVY-U-SpNatA and pBEVY-U-SpNatA-ΔN-K6E were transformed into the ScNatAΔ strain using standard yeast techniques [45]. In addition, the wild-type strain and the ScNatAΔ strain were transformed with empty pBEVY-U plasmid. Transformants were selected and maintained on SD-Ura agar [0.67% (w/v) yeast nitrogen base without amino acids, 0.2% (w/v) yeast drop-out mix without uracil, 2% (w/v) glucose, and 2% (w/v) agar].

Immunoblotting

Yeast whole-cell protein extracts were prepared by alkaline treatment as previously described [46]. Protein extracts were separated by SDS-PAGE and analyzed by immunoblotting. The immunoblots were probed with rabbit polyclonal anti-HA tag (1:10,000, Abcam, ab9110), mouse monoclonal anti-V5 tag (1:10,000, Invitrogen, #R960-25), and rabbit polyclonal anti-Zwf1 (1:15,000, Sigma, A9521). HRP-conjugated rabbit or mouse anti-goat IgG were used as secondary antibodies (1:10,000, Bio-Rad, #1706515 and #1706516). All antibodies were diluted in 1X TBS containing 5% nonfat dry milk (w/v) and 0.05% Tween-20. The immunoblots were developed using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, #34095) followed by detection and imaging using VersaDoc MP 5000 from Bio-Rad.

Yeast growth assay

Wild-type and ScNatAΔ yeast strains were grown in <span class="Chemical">SD-Ura at 30 °C to early log phase (OD600 0.8–1.0) and adjusted to 1 OD600/ml. Ten-fold serial dilutions with sterile milliQ water were spotted (2 µl) onto YPD [1% (w/v) yeast extract, 2% (w/v) peptone (w/v), 0.012% (w/v) adenine, 2% (w/v) glucose, and 2% (w/v) agar] and SD-Ura agar [0.67% (w/v) yeast nitrogen base without amino acids, 0.2% (w/v) yeast drop-out mix without uracil, 2% (w/v) glucose, and 2% (w/v) agar]. The plates were incubated at 30 or 38 °C for 2 days and imaged with spImager from S&P Robotics.

Results and discussion

Naa15 constitutes the auxiliary part of the NatA complex and regulates its activity in a dual manner: by anchoring the catalytic subunit <Species">span class="Gene">Naa10 to the ribosome so that nascent polypeptide chains are presented to Naa10 which in turn acetylates the N-terminal amino group, and secondly by modulating the catalytic site of Naa10 to match the broad spectrum of its in vivo substrates [40]. Both Naa10 and Naa15 are highly conserved in eukaryotes [35]. The human Naa15 protein share 46.6% and 43.4% sequence similarity with its S. pombe and S. cerevisiae homologues, respectively, with largest variation at the C-terminus (Fig. 1). The sequence similarity between SpNaa15 and ScNaa15 is 44.5%. Using the structure of SpNatA (Fig. 2a) [41], Magin et al. [44] identified two conserved electropositive regions (EPR) in Naa15, an N-terminal region and an internal basic helix near the C-terminus, that could potentially facilitate the interaction between NatA and the ribosomes. Moreover, they generated a series of mutants targeting these two regions. They showed, using an in vitro N-terminal acetylation assay, that the NatA variant SpNaa15 ΔN K6E (p.Δ1-109, K605E, K606E, K609E, K610E, K612E, K613E) (Fig. 2b) was enzymatically active towards the serine-starting peptide SESS-(corresponding to the N-terminus of HMGA1), representing a classical NatA substrate. They also revealed with NatA–ribosome co-sedimentation and gel filtration analyses that the ΔN K6E mutant was unable to bind ribosomes.
Fig. 1

Multiple sequence alignment of Naa15 from H. sapiens (Hs), S. pombe (Sp), and S. cerevisiae (Sc). The alignment was generated in Clustal Omega [51] and edited in Jalview [52]. The N-terminal region (EPR1) and the internal basic helix (EPR2) are indicated in blue. Light blue color indicates hydrophobic residues, red indicates basic residues, magenta indicates acidic residues, green indicates polar residues, pink indicates cysteines, orange indicates glycines, yellow indicates prolines, and cyan indicates aromatic residues

Fig. 2

Schematic representation of the SpNatA structure and constructs used. a Cartoon and b surface representation of the SpNatA complex, showing SpNaa15 in teal and SpNaa10 in orange. The N-terminal region (transparent teal) and the internal basic helix (raspberry) are indicated. The SpNatA structure was generated from PDB ID: 4KVO using PyMOL version 2.0 Schrödinger, LLC. c Schematic of the SpNatA constructs used with the two predicted electropositive regions (EPR1 and 2) indicated. Blue, HA-tag; teal, SpNaa15; raspberry, mutated amino acid residues; orange, SpNaa10; purple, V5-tag. Note that for SpNaa10 only residues 1–156 out of the 177 total residues were used

Multiple sequence alignment of Naa15 from <Species">span class="Species">H. sapiens (Hs), S. pombe (Sp), and S. cerevisiae (Sc). The alignment was generated in Clustal Omega [51] and edited in Jalview [52]. The N-terminal region (EPR1) and the internal basic helix (EPR2) are indicated in blue. Light blue color indicates hydrophobic residues, red indicates basic residues, magenta indicates acidic residues, green indicates polar residues, pink indicates cysteines, orange indicates glycines, yellow indicates prolines, and cyan indicates aromatic residues Schematic representation of the SpNatA structure and constructs used. a Cartoon and b surface representation of the SpNatA complex, showing SpNaa15 in teal and Sp<Species">span class="Gene">Naa10 in orange. The N-terminal region (transparent teal) and the internal basic helix (raspberry) are indicated. The SpNatA structure was generated from PDB ID: 4KVO using PyMOL version 2.0 Schrödinger, LLC. c Schematic of the SpNatA constructs used with the two predicted electropositive regions (EPR1 and 2) indicated. Blue, HA-tag; teal, SpNaa15; raspberry, mutated amino acid residues; orange, SpNaa10; purple, V5-tag. Note that for SpNaa10 only residues 1–156 out of the 177 total residues were used The NatA complex is conserved from <Species">span class="Species">yeast to human, as shown by complementation of growth phenotypes and partial rescue of the N-terminal acetylome [35]. With this in mind, we developed a simple functional assay for NatA mutations that is based on the temperature-sensitive growth phenotype of budding yeast lacking NatA [35, 36, 47, 48]. To functionally assess the SpNaa15 ΔN K6E mutant, we transformed a ard1Δ/nat1Δ double deletion strain (ScNatAΔ) (Fig. 3a) with a bidirectional expression vector encoding either SpNatA wild-type or SpNatA ΔN K6E (schematic of the constructs is shown in Fig. 2c). SpNatA expression in the ScNatAΔ deletion strain was confirmed by immunoblot analysis using anti-HA and anti-V5 to detect HA-SpNaa15 and SpNaa10-V5, respectively (Fig. 3b). As expected the SpNaa15 ΔN K6E variant had a lower molecular weight than full-length SpNaa15 (HA-SpNaa15, 746 amino acids, 85.5 kDa). We also observed a non-specific band around 80 kDa, which is caused by the secondary antibody used.
Fig. 3

SpNatA ΔN-K6E does not rescue growth of ScNatAΔ cells at high temperature. a Confirming gene disruption of ARD1 and NAT1 in a ScNatAΔ strain by colony PCR using ARD1 and NAT1 primers. ARD1-specific PCR product 1024 bp (ARD1 717 bp + gene-specific sequence 307 bp). NAT1-specific PCR product 2976 bp (NAT1 2565 bp + gene-specific sequence 411 bp). b SpNatA expression was confirmed by immunoblot analyses using anti-HA (to detect HA-SpNaa15) and anti-V5 (to detect SpNaa10-V5). Anti-Zwf1 served as loading control. c Wild-type (W303-1A) and ScNatAΔ yeast cells transformed with empty pBEVY plasmid, wild-type SpNatA, or SpNatA ΔN-K6E were grown to early log-phase in SD-Ura medium. Ten-fold serial dilutions were spotted onto YPD and SD-Ura agar plates and incubated for 2 days at 30 or 38 °C. wt; wild-type

SpNatA ΔN-K6E does not rescue growth of ScNatAΔ cells at high temperature. a Confirming gene disruption of ARD1 and <Species">span class="Gene">NAT1 in a ScNatAΔ strain by colony PCR using ARD1 and NAT1 primers. ARD1-specific PCR product 1024 bp (ARD1 717 bp + gene-specific sequence 307 bp). NAT1-specific PCR product 2976 bp (NAT1 2565 bp + gene-specific sequence 411 bp). b SpNatA expression was confirmed by immunoblot analyses using anti-HA (to detect HA-SpNaa15) and anti-V5 (to detect SpNaa10-V5). Anti-Zwf1 served as loading control. c Wild-type (W303-1A) and ScNatAΔ yeast cells transformed with empty pBEVY plasmid, wild-type SpNatA, or SpNatA ΔN-K6E were grown to early log-phase in SD-Ura medium. Ten-fold serial dilutions were spotted onto YPD and SD-Ura agar plates and incubated for 2 days at 30 or 38 °C. wt; wild-type We next performed a Species">yeast growth assay where <Species">span class="Chemical">serial dilutions of wild-type (W303-1A) + empty vector, ScNatAΔ + empty vector, ScNatAΔ + SpNatA, or ScNatAΔ + SpNatA ΔN K6E strains was spotted onto YPD and selective SD-Ura media. In agreement with previous studies, we observed reduced growth of the NatA knockout strain at elevated temperatures (Fig. 3c). Moreover, overexpression of the SpNatA complex rescued the growth defect of ScNatAΔ mutant cells. Consequently, SpNatA can functionally replace ScNatA, suggesting that the NatA complex is structurally very similar in the two yeast species. This observation was made on both YPD and SD-Ura growth media. Thus, ScNatAΔ mutant cells are able to retain the SpNatA plasmid even in the absence of selection due to the high selective pressure on cell viability. Overexpression of the SpNatA ΔN K6E mutant, however, failed to rescue the temperature-sensitive growth phenotype of ScNatAΔ. Although the SpNatA ΔN K6E variant was enzymatically active in vitro [44], this finding indicates that ribosome binding is essential for normal NatA function in vivo. Favorable electrostatic interactions appear to be a common feature for the interaction between molecular chaperones involved in co-translational folding and the ribosome [43, 44]. The NatA complex associates with the ribosome in a salt-sensitive manner, indicating an association mediated by ionic interactions [40, 44, 49]. Intriguingly, both the positively charged N-terminal region and the positively charged internal helix in Naa15 are situated on the same side of NatA and facing the ribosomal exit tunnel [44]. Thus, modifications within these two regions may interfere with NatA’s ability to interact with the ribosome and perform co-translational N-terminal acetylation by affecting the orientation and the electrostatic potential. The binding to Naa10 and NAT-activity were not affected in vitro [44]. Nevertheless, overexpression of SpNatA ΔN K6E seems to confer ScNatAΔ cells with slightly better growth at 38 °C compared to empty vector, suggesting that this mutant may have a small residual capacity to acetylate selected substrates controlling this phenotype. It may either mean that the mutant has retained a weak ability to associate with ribosomes, or has a residual capacity to perform post-translational N-terminal acetylation. In conclusion, this <span class="Species">yeast model complements the findings from the Magin study and supports the notion that EPR1 and EPR2 of the ribosome binding subunit <span class="Gene">Naa15 plays important structural role for correct and efficient NatA activity during protein synthesis. Mutation in these electropositive regions could have deleterious effects and, as suggested by Magin et al. could be used for therapeutic targeting of NatA activity by modifying ribosome binding.

Limitations

We acknowledge that this study only provide preliminary insights into the interaction between NatA and the ribosome and that it does not exclude the possibility that other regions on the NatA surface or binding factors are important for ribosome binding. For example, the NatA complex also associates with <span class="Gene">Naa50 [40] and in multicellular eukaryotes the chaperone-like protein HYPK (Huntingtin-interacting protein K) [50]. We focused on SpNatA ΔN K6E since Magin et al. [44] showed that this mutant displayed the most severe ribosomal pulldown effect. Incorporation of a V5-tag C-terminal of SpNaa10 and a HA-tag N-terminal of Sp<Species">span class="Gene">Naa15 may affect SpNatA complex formation, ribosome binding, and/or enzymatic activity, but wild-type and mutant SpNaa15 were assayed and compared with identical tags. We have not performed any SpNatA-ribosome pulldown experiments using <span class="Species">yeast lysates.
  52 in total

1.  Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae.

Authors:  B Polevoda; J Norbeck; H Takakura; A Blomberg; F Sherman
Journal:  EMBO J       Date:  1999-11-01       Impact factor: 11.598

2.  Truncating Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies.

Authors:  Hanyin Cheng; Avinash V Dharmadhikari; Sylvia Varland; Ning Ma; Deepti Domingo; Robert Kleyner; Alan F Rope; Margaret Yoon; Asbjørg Stray-Pedersen; Jennifer E Posey; Sarah R Crews; Mohammad K Eldomery; Zeynep Coban Akdemir; Andrea M Lewis; Vernon R Sutton; Jill A Rosenfeld; Erin Conboy; Katherine Agre; Fan Xia; Magdalena Walkiewicz; Mauro Longoni; Frances A High; Marjon A van Slegtenhorst; Grazia M S Mancini; Candice R Finnila; Arie van Haeringen; Nicolette den Hollander; Claudia Ruivenkamp; Sakkubai Naidu; Sonal Mahida; Elizabeth E Palmer; Lucinda Murray; Derek Lim; Parul Jayakar; Michael J Parker; Stefania Giusto; Emanuela Stracuzzi; Corrado Romano; Jennifer S Beighley; Raphael A Bernier; Sébastien Küry; Mathilde Nizon; Mark A Corbett; Marie Shaw; Alison Gardner; Christopher Barnett; Ruth Armstrong; Karin S Kassahn; Anke Van Dijck; Geert Vandeweyer; Tjitske Kleefstra; Jolanda Schieving; Marjolijn J Jongmans; Bert B A de Vries; Rolph Pfundt; Bronwyn Kerr; Samantha K Rojas; Kym M Boycott; Richard Person; Rebecca Willaert; Evan E Eichler; R Frank Kooy; Yaping Yang; Joseph C Wu; James R Lupski; Thomas Arnesen; Gregory M Cooper; Wendy K Chung; Jozef Gecz; Holly A F Stessman; Linyan Meng; Gholson J Lyon
Journal:  Am J Hum Genet       Date:  2018-04-12       Impact factor: 11.025

3.  The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation.

Authors:  Thomas Arnesen; Kristian K Starheim; Petra Van Damme; Rune Evjenth; Huyen Dinh; Matthew J Betts; Anita Ryningen; Joël Vandekerckhove; Kris Gevaert; Dave Anderson
Journal:  Mol Cell Biol       Date:  2010-02-12       Impact factor: 4.272

4.  A splice donor mutation in NAA10 results in the dysregulation of the retinoic acid signalling pathway and causes Lenz microphthalmia syndrome.

Authors:  Taraneh Esmailpour; Hamidreza Riazifar; Linan Liu; Sandra Donkervoort; Vincent H Huang; Shreshtha Madaan; Bassem M Shoucri; Anke Busch; Jie Wu; Alexander Towbin; Robert B Chadwick; Adolfo Sequeira; Marquis P Vawter; Guoli Sun; Jennifer J Johnston; Leslie G Biesecker; Riki Kawaguchi; Hui Sun; Virginia Kimonis; Taosheng Huang
Journal:  J Med Genet       Date:  2014-01-15       Impact factor: 6.318

5.  Jalview Version 2--a multiple sequence alignment editor and analysis workbench.

Authors:  Andrew M Waterhouse; James B Procter; David M A Martin; Michèle Clamp; Geoffrey J Barton
Journal:  Bioinformatics       Date:  2009-01-16       Impact factor: 6.937

6.  The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways.

Authors:  M Whiteway; J W Szostak
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

7.  Control of protein quality and stoichiometries by N-terminal acetylation and the N-end rule pathway.

Authors:  Anna Shemorry; Cheol-Sang Hwang; Alexander Varshavsky
Journal:  Mol Cell       Date:  2013-04-18       Impact factor: 17.970

8.  N alpha acetylation is required for normal growth and mating of Saccharomyces cerevisiae.

Authors:  F J Lee; L W Lin; J A Smith
Journal:  J Bacteriol       Date:  1989-11       Impact factor: 3.490

9.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

10.  A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1).

Authors:  Thomas Arnesen; Darina Gromyko; Diane Kagabo; Matthew J Betts; Kristian K Starheim; Jan Erik Varhaug; Dave Anderson; Johan R Lillehaug
Journal:  BMC Biochem       Date:  2009-05-29       Impact factor: 4.059

View more
  6 in total

Review 1.  Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal Acetyltransferases.

Authors:  Henriette Aksnes; Rasmus Ree; Thomas Arnesen
Journal:  Mol Cell       Date:  2019-03-13       Impact factor: 17.970

Review 2.  Protein N-Terminal Acetylation: Structural Basis, Mechanism, Versatility, and Regulation.

Authors:  Sunbin Deng; Ronen Marmorstein
Journal:  Trends Biochem Sci       Date:  2020-09-08       Impact factor: 13.807

3.  Human NAA30 can rescue yeast mak3∆ mutant growth phenotypes.

Authors:  Adrian Drazic; Sylvia Varland
Journal:  Biosci Rep       Date:  2021-03-26       Impact factor: 3.840

4.  Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency.

Authors:  Kris Gevaert; Christine Seidman; J G Seidman; Tarsha Ward; Warren Tai; Sarah Morton; Francis Impens; Petra Van Damme; Delphi Van Haver; Evy Timmerman; Gabriela Venturini; Kehan Zhang; Min Young Jang; Jon A L Willcox; Alireza Haghighi; Bruce D Gelb; Wendy K Chung; Elizabeth Goldmuntz; George A Porter; Richard P Lifton; Martina Brueckner; H Joseph Yost; Benoit G Bruneau; Joshua Gorham; Yuri Kim; Alexandre Pereira; Jason Homsy; Craig C Benson; Steven R DePalma; Sylvia Varland; Christopher S Chen; Thomas Arnesen
Journal:  Circ Res       Date:  2021-02-09       Impact factor: 17.367

5.  Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway.

Authors:  Hyae Yon Kweon; Mi-Ni Lee; Max Dorfel; Seungwoon Seo; Leah Gottlieb; Thomas PaPazyan; Nina McTiernan; Rasmus Ree; David Bolton; Andrew Garcia; Michael Flory; Jonathan Crain; Alison Sebold; Scott Lyons; Ahmed Ismail; Elaine Marchi; Seong-Keun Sonn; Se-Jin Jeong; Sejin Jeon; Shinyeong Ju; Simon J Conway; Taesoo Kim; Hyun-Seok Kim; Cheolju Lee; Tae-Young Roh; Thomas Arnesen; Ronen Marmorstein; Goo Taeg Oh; Gholson J Lyon
Journal:  Elife       Date:  2021-08-06       Impact factor: 8.713

Review 6.  Possible Catch-Up Developmental Trajectories for Children with Mild Developmental Delay Caused by NAA15 Pathogenic Variants.

Authors:  Yu Tian; Hua Xie; Shenghai Yang; Shaofang Shangguan; Jianhong Wang; Chunhua Jin; Yu Zhang; Xiaodai Cui; Yanyu Lyu; Xiaoli Chen; Lin Wang
Journal:  Genes (Basel)       Date:  2022-03-18       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.